7. Value-based care, pay-for-performance, and patient-centricity.
While these issues are on everyone’s mind, executives must not overlook the interdependence of these topics, says Jennifer Bright, acting executive director, the Innovation and Value Initiative, a collaboration of academics, patient advocacy organizations, payers, life sciences companies.
“Executives can benefit from models that integrate multiple measurement tools with the patient perspective at the forefront, so they can move beyond short-term price focus to assess real-world value,” Bright says.
Rick R. Suarez, vice president, U.S. market access, AstraZeneca, agrees. “With the dynamic external environment, there is a greater need than ever to move the system toward a focus on value and improved patient outcomes,” he says.